Soluble PD-1 and PD-L1: predictive and prognostic significance in cancer

被引:256
|
作者
Zhu, Xinxin [1 ]
Lang, Jinghe [1 ]
机构
[1] Chinese Acad Med Sci, Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Obstet & Gynecol, Beijing, Peoples R China
关键词
soluble; PD-1; PD-L1; tumor immunity; biomarker; CELL LUNG-CANCER; DEATH-LIGAND; PROGRAMMED DEATH-1; ANTITUMOR IMMUNITY; T-CELLS; HEPATOCELLULAR-CARCINOMA; CLINICAL-SIGNIFICANCE; POOR-PROGNOSIS; PD-1/PD-L1; BLOCKADE; CIRCULATING PD-L1;
D O I
10.18632/oncotarget.18311
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The membrane-bound molecules programmed death 1 (PD-1) and its ligand PD-L1 (PD-1/PD-L1) belong to the immune checkpoint pathway. PD-1 pathway downregulates effector T cells in immune response, thereby causing immune suppression. Recent studies have revealed that membrane-bound PD-1 and PD-L1 also have soluble forms. These soluble forms increase the complexity and diversity of the composition and function of the PD-1/PD-L1 signaling pathway. However, the exact roles of these molecules remain unknown. The objective of this systematic review was to elucidate the biological significance of soluble PD-1/PD-L1 in human cancers and evaluate whether they are potential diagnostic, therapeutic, or prognostic biomarkers. We expect to provide new clues for future research on soluble PD-1/PD-L1 pathway in human malignant tumors.
引用
收藏
页码:97671 / 97682
页数:12
相关论文
共 50 条
  • [41] The combination of soluble forms of PD-1 and PD-L1 as a predictive marker of PD-1 blockade in patients with advanced cancers: a multicenter retrospective study
    Kurosaki, Takashi
    Chamoto, Kenji
    Suzuki, Shinichiro
    Kanemura, Hiroaki
    Mitani, Seiichiro
    Tanaka, Kaoru
    Kawakami, Hisato
    Kishimoto, Yo
    Haku, Yasuharu
    Ito, Katsuhiro
    Sato, Toshiyuki
    Suminaka, Chihiro
    Yamaki, Mami
    Chiba, Yasutaka
    Yaguchi, Tomonori
    Omori, Koichi
    Kobayashi, Takashi
    Nakagawa, Kazuhiko
    Honjo, Tasuku
    Hayashi, Hidetoshi
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [42] Blocking the PD-1/PD-L1 axis for cancer therapy
    Drake, C.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : S12 - S13
  • [43] PD-1/PD-L1 and DNA Damage Response in Cancer
    Kciuk, Mateusz
    Kolat, Damian
    Kaluzinska-Kolat, Zaneta
    Gawrysiak, Mateusz
    Drozda, Rafal
    Celik, Ismail
    Kontek, Renata
    CELLS, 2023, 12 (04)
  • [44] PD-1/PD-L1 blockade in renal cell cancer
    Beckermann, Kathryn E.
    Johnson, Douglas B.
    Sosman, Jeffrey A.
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2017, 13 (01) : 77 - 84
  • [45] Cancer immunotherapy and the PD-1/PD-L1 checkpoint pathway
    Barclay, Jonathan
    Creswell, Joanne
    Leon, Juan
    ARCHIVOS ESPANOLES DE UROLOGIA, 2018, 71 (04): : 393 - 399
  • [46] Combination therapy with PD-1 or PD-L1 inhibitors for cancer
    Hidetoshi Hayashi
    Kazuhiko Nakagawa
    International Journal of Clinical Oncology, 2020, 25 : 818 - 830
  • [47] Prognostic value of PD-1, PD-L1 and PD-L2 deserves attention in head and neck cancer
    Jiang, Siqing
    Li, Xin
    Huang, Lihua
    Xu, Zhensheng
    Lin, Jinguan
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [48] Combination therapy with PD-1 or PD-L1 inhibitors for cancer
    Hayashi, Hidetoshi
    Nakagawa, Kazuhiko
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2020, 25 (05) : 818 - 830
  • [49] PD-1 AND PD-L1 EXPRESSION ON THE PROGNOSIS OF OVARIAN CANCER
    Li, R. P.
    Li, W. Y.
    Guo, Y. Z.
    JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS, 2019, 33 (04): : 1161 - 1166
  • [50] PD-1/PD-L1 pathway: current researches in cancer
    Han, Yanyan
    Liu, Dandan
    Li, Lianhong
    AMERICAN JOURNAL OF CANCER RESEARCH, 2020, 10 (03): : 727 - 742